A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
Year: 2024
Type: article
Abstract: The age-associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH-focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19925
Authors: Tamanna Haque, Aditi Shastri, Pinkal Desai, Zhuoer Xie, Danielle Hammond, Zoe King, Ashwin Kishtagari, Yazan F. Madanat, Yasmin Abaza, Alexander J. Silver, Abhay Singh, Uma M. Borate, J. Brett Heimlich, David A. Slosky, Kelly L. Bolton, Mrinal S. Patnaik, Alexander G. Bick, Amit K. Verma, Siddhartha Jaiswal, David P. Steensma, Michael R. Savona
Institutions: Memorial Sloan Kettering Cancer Center, Montefiore Einstein Comprehensive Cancer Center, Cornell University, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, The University of Texas Southwestern Medical Center, Northwestern University, Cleveland Clinic, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Wisconsin–Madison, UW Health University Hospital, Washington University in St. Louis, Mayo Clinic, Stanford Medicine, Stanford University, University of Massachusetts System
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4405174554